Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor results of the drug utilization observation studies

Pharmacopsychiatry

Volumn 32, Issue 2, 1999, Pages 61-67

  Delini Stula, A ^a,f   Baier, D ^b   Kohnen, R ^c   Laux, G ^d   Philipps, M ^e   Scholz, H J ^b  

^a CNS Medical Research Counselling   (Switzerland)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c IMEREM   (Germany)

^d District Hospital Gabersee   (Germany)

^e Hospital Landshut   (Germany)

^f CM RC   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILD; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL;

EID: 0032944240     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979193     Document Type: Article

References (26)

1. Amrein, R., S. R. Allen, T. W. Güntert, D. Hartmann, T. Lorscheid, M. P. Schoerlin, D. Vranesic: The pharmacology of reversible monoamine oxidase inhibitors. Br. J. Psychiatry 155 (Suppl. 6) (1989) 66-71
2. Burkard, W. P., E. P. Bonetti, M. Da Prada, J. R. Martin, P. Polc, R. Schaffner, R. Scherschlicht, F. Heffi, R. M. Müller, P. C. Wyss, W. Haefely: Pharmacological profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248 (1989) 391-399
3. Council for International Organisations of Medical Sciences (CIOMS): International reporting of periodic drug-safety update summaries. CIOMS, Genf (1992)
4. Coupland, N. J., S. J. Wilson, J. P. Potokar, C. E. Bell, J. E. Bailey, D. J. Nutt: A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. I Clin. Psychopharmacol 10 (1995) 229-238
5. Dechant, K. L., S. P. Clissold: Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 41 (1991) 225-253
6. Dukes, M. N. G., L. Beeley: Side effects of drugs. Annual 12 (eds.: Blackwell B., J. S. Simon) Vol. 2 Antidepressant drugs. Elsevier, Amsterdam (1988)
7. Fallon B., B. Foote, B. T. Walsh, S. P. Roose: "Spontaneous" hypertensive episodes with monoamine oxidase inhibitors. J. Clin. Psychiatry 49 (1988) 163-165
8. Feighner, J. P.: Cardiovascular safety in depressed patients: focus on venlafaxine. J. Clin. Psychiatry 56 (1995) 574-579
9. Glassman, A. H., J. T. Bigger: Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch. Gen. Psychiatry 38 (1981) 815-820
10. Goodman-Gilman, P., T. W. Rall, T. S. Nies, P. Taylor: The pharmacological basis of therapeutics. Pergamon Press, New York (1990)
11. Guelfi, J. D., C. Payan, J. Fermanian, A.-M. Pedarriosse, R. Manfredi: Moclobemide versus clomipramine in endogenous depression: a double-blind randomised clinical trial. B. J. Clin. Psychiatry 160 (1990) 519-524
12. Hayes, P. E., C. A. Kristoff: Adverse reaction to five new antidepressants. Clin. Pharmacy 5 (1986) 471-480
13. Hetze, W.: Das Sicherheitsprofil von Moclobemid in klinischen Studien. In: Steinberg, R. (ed.) RIMA in der antidepressiven Therapie. MMV Verlag München (1993)
14. Keck, P. E., A. Vuckovic, H. G. Pope, A. A. Nierenberg, G. W. Gribble, K. White: Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment. J. Clin. Psychopharmacol 9 (1989) 203-206
15. Laux, G., H. J. Scholz, D. Baier: Ergebnisse der Anwendungsbeobachtung zu Moclobemid bei Allgemeinärzten und Internisten in Deutschland. Psychopharmacother (Suppl. 2): (1994) 19-26
16. Laux, G., M. Philipp, R. Kohnen: Hypertension with moclobemide. Lancet 347: 1330
17. Marley E (1977): Monoamine oxidase inhibitors. In: Drug Interactions. Graham-Smith D. G. (ed.), Baltimore, University Park Press (1996) 178-194
18. Moll, E., N. Neumann, W. Schmid-Burgk, M. Stabl, R. Amrein: Safety and efficacy during long-term treatment with moclobemide. Clin. Neuropharmacol. 17 (1994) S74-S87
19. Philipp, M., D. Baier: Moclobemid bei Depression. Ergebnisse einer Anwendungsbeobachtung bei Psychiatern und Neurologen. TW Neurologie Psychiatrie 9 (1995) 4-7
20. Philipp, M., D. Baier: Personal communication (1996)
21. Ray, W. A., M. R. Griffan, W. Schaffner, D. K. Baugh, L. J. Melton: Psychotropic drug use and the risk of hip fracture. New England J. Med. 316 (1987) 363-369
22. Rudorfer, M., H. K. Manji, W. Z. Poner: Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety 10 (1994) 18-46
23. Tesar, G. E., J. F. Rosenbaum, J. Biederman: Orthostatic hypotension and antidepressant pharmacotherapy. Psychopharmacol Bull 23 (1987) 182-186
24. Versiani, M., A. E. Nardi, I. L. V. Figueira, M. Stabl: Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr. Scand. 82 (Suppl. 360) (1990) 21-28
25. Waldmeier, P. C., P. A. Baumann, A. Delini-Stula, R. Bernasconi, K. Sigg, O. Buech, A. E. Felner: Characterisation of a new, reversible and short-acting inhibitor of type A monoamine oxidase. In: Beckman, H., Riederer P. (eds.) Mod. Probl. Pharmacopsychiatr. (vol. 19), Monoamine oxidase and its selective inhibitors: new concepts in therapy and research, Karger, Basel (1983) 31-59
26. Youdim, M. B. H., J. P. M. Finberg, K. F. Tripton: Monoamine oxidase. In: Trendelenburg, I. U., Werner N. (eds.) Catecholamines, Springer, Berlin Heidelberg New York (1988) 119-192